Copyright © 2016
Aridis Pharmaceuticals, Inc.
5941 Optical Court, San Jose, CA 95138
PanaecinTM (Gallium Citrate): Novel anti-
PanaecinTM(gallium Citrate) Molecule.
PanaecinTM has broad bactericidal activity against Gram negative and Gram positive bacteria, including antibiotic resistant strains and highly antibiotic resistant biofilms. The core activity of PanaecinTM is derived from gallium, which functions as a potent iron analog and inhibits critical iron dependent enzymatic pathways in bacteria such as DNA synthesis, metabolic conversion, electron transport and oxidative stress defense. Its inhibitory activity is unaffected by resistance to antibiotics and extends to bacteria growing in mature biofilms as well as preventing biofilm formation. PanaecinTM is Aridis’ lead broad spectrum product for the treatment of life threatening bacterial lung infections, including P. aeruginosa (Pa) infections in patients with cystic fibrosis (CF), ventilator-
PanaecinTM also has antimicrobial activity against other common bacterial lung infections including S. aureus, methicillin resistant S. aureus (MRSA), and B. cepacia. Current treatments for CF are either palliative or ineffective in clearing the underlying chronic P. aeruginosa infection. The initial indications for PanaecinTM have a market potential in excess of $1B. These include P. aeruginosa lung infections, which affects ~80% of adult cystic fibrosis (CF) patients.
This product candidate is currently in late preclinical stage and has previously received approximately $18 million in funding from the NIH and the Department of Defense. Preclinical animal studies in disease models are completed and clinical trial drug supplies have been manufactured.
Breakthrough Therapies for
Antibiotic Resistant Infections